id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-309914-1lpl26eo	Peterson, Danielle	The use of Janus kinase inhibitors in the time of SARS-CoV-2	2020-04-09		.txt	text/plain	503	40	60	During the time of the SARS-CoV-2 pandemic, questions arise regarding patients being treated with 37 immunomodulatory therapies. In particular, is there an increased risk of acquiring the infection or 38 experiencing a worse outcome from SARS-CoV-2? we can look at safety data from clinical trials to try to understand patient susceptibility to different 40 infections. In light of the 42 growing off-label use of JAKi in dermatology in addition to pharmaceutical industry sponsored clinical 43 trials of JAKi for alopecia areata, atopic dermatitis, vitiligo, etc, dermatologists need data to better 44 understand the risks of JAKi treatment in order to best manage and counsel our patients during this 45 unique time. We analyzed and collated Adverse Events data from JAKi clinical trials. We also collated pulmonary 53 toxicities of JAKi to identify potential risks of worsening severe respiratory disease from SARS-CoV-2, and 54 such toxicities are all but absent.	./cache/cord-309914-1lpl26eo.txt	./txt/cord-309914-1lpl26eo.txt